Hepatitis vaccines are essential tools in preventing viral infections that target the liver, specifically Hepatitis A and Hepatitis B. The Hepatitis A vaccine is vital for safeguarding against contamination-related infections, commonly transmitted through contaminated food or water. It is particularly recommended for travelers to regions with a higher prevalence of Hepatitis A. The Hepatitis B vaccine is a key component in preventing chronic Hepatitis B infections, which can lead to severe liver diseases, including cirrhosis and liver cancer. Administered as part of routine childhood immunization schedules, it is also recommended for adults, especially those at an increased risk of exposure. Combined vaccines, such as the Hepatitis A and B combination, provide comprehensive protection against both viruses. Beyond individual protection, widespread vaccination efforts contribute significantly to public health by reducing the overall burden of Hepatitis-related diseases globally. Continuous research and development efforts aim to expand vaccine coverage, addressing additional Hepatitis strains and reinforcing the commitment to preventing and controlling Hepatitis infections on a global scale. Regular vaccination campaigns and healthcare initiatives remain critical in promoting broad immunization against Hepatitis.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States